Clinical Trials
2 trialsNCT04003610 2025-11-04
Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)
Incyte Corporation
Phase 2 Terminated
NCT02872714 2025-08-14
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)
Incyte Corporation
Phase 2 Completed